Comments
Zydus Lifesciences Ltd’s shares were up by 1.19 per cent after it launched the advanced prostate cancer drug Rexigo in India. This drug works by suppressing testosterone to manage prostate cancer.
Rexigo is priced ₹6,995 per month, which is nearly half the cost of other injectable options, the company said.
It added that relugolix, the active ingredient in Rexigo, is recognised as the only oral option among androgen deprivation therapy (ADT) drugs. The drug ensures sustained testosterone suppression throughout the treatment period, with a faster recovery of testosterone levels once the medication is stopped, the company said.
The shares were up by 1.19 per cent Rs ₹757.75 at 10.21 am on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.